Kura Oncology to Report First Quarter 2026 Financial Results
Kura Oncology (Nasdaq: KURA) will report first quarter 2026 financial results after market close on Tuesday, May 12, 2026.
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) will report first quarter 2026 financial results after market close on Tuesday, May 12, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a corporate update. A live webcast and archived replay will be available on the company Investors website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – KURA
In the May 5 session, KURA gained 0.43%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings date
- May 12, 2026
- Q1 2026 financial results to be reported after U.S. market close
- Conference call time
- 4:30 p.m. ET / 1:30 p.m. PT
- Management webcast and call to discuss Q1 2026 results
- Share price
- $9.25
- Price prior to Q1 2026 earnings date announcement
- Daily price move
- 5.47%
- Change over the last 24 hours before this news
- 52-week range
- $5.45 – $12.49
- Low and high over the past 52 weeks
- Market capitalization
- $778,448,914
- Equity value prior to Q1 2026 earnings date news
Previous Earnings date Reports
-
Set date and call details for Q4 and full‑year 2025 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2026 financial results after the close of U.S. financial markets on Tuesday, May 12, 2026. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update.
The live webcast and archived replay of the event may be accessed on the Investors section of the Company’s website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.